DE602004012759D1 - Behandlung von fibrosen - Google Patents

Behandlung von fibrosen

Info

Publication number
DE602004012759D1
DE602004012759D1 DE602004012759T DE602004012759T DE602004012759D1 DE 602004012759 D1 DE602004012759 D1 DE 602004012759D1 DE 602004012759 T DE602004012759 T DE 602004012759T DE 602004012759 T DE602004012759 T DE 602004012759T DE 602004012759 D1 DE602004012759 D1 DE 602004012759D1
Authority
DE
Germany
Prior art keywords
treatment
fibroses
insp035
scleroderma
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004012759T
Other languages
English (en)
Other versions
DE602004012759T2 (de
Inventor
Christine Power
Yan Lavrovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Publication of DE602004012759D1 publication Critical patent/DE602004012759D1/de
Application granted granted Critical
Publication of DE602004012759T2 publication Critical patent/DE602004012759T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE602004012759T 2003-09-08 2004-09-07 Behandlung von fibrosen Active DE602004012759T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102723 2003-09-08
EP03102723 2003-09-08
PCT/EP2004/052077 WO2005023288A1 (en) 2003-09-08 2004-09-07 Treatment of fibrotic disease

Publications (2)

Publication Number Publication Date
DE602004012759D1 true DE602004012759D1 (de) 2008-05-08
DE602004012759T2 DE602004012759T2 (de) 2008-07-17

Family

ID=34259208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012759T Active DE602004012759T2 (de) 2003-09-08 2004-09-07 Behandlung von fibrosen

Country Status (10)

Country Link
US (1) US8283307B2 (de)
EP (1) EP1663294B1 (de)
JP (1) JP4723496B2 (de)
AT (1) ATE390144T1 (de)
AU (1) AU2004269927B2 (de)
CA (1) CA2535021A1 (de)
DE (1) DE602004012759T2 (de)
ES (1) ES2300817T3 (de)
IL (1) IL174134A0 (de)
WO (1) WO2005023288A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
JP6675605B2 (ja) * 2014-10-10 2020-04-01 国立大学法人高知大学 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
IL127153A0 (en) 1996-06-06 1999-09-22 Smithkline Beecham Plc Fragments of leptin (ob protein)
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002066071A2 (en) * 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
CA2440747A1 (en) * 2001-03-15 2002-09-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1658895A (zh) * 2002-04-10 2005-08-24 应用研究系统Ars股份公司 护骨素在治疗和／或预防纤维变性疾病中的应用

Also Published As

Publication number Publication date
AU2004269927A1 (en) 2005-03-17
ES2300817T3 (es) 2008-06-16
DE602004012759T2 (de) 2008-07-17
JP4723496B2 (ja) 2011-07-13
EP1663294B1 (de) 2008-03-26
ATE390144T1 (de) 2008-04-15
JP2007505082A (ja) 2007-03-08
AU2004269927B2 (en) 2009-09-17
US8283307B2 (en) 2012-10-09
WO2005023288A1 (en) 2005-03-17
CA2535021A1 (en) 2005-03-17
EP1663294A1 (de) 2006-06-07
WO2005023288A8 (en) 2005-05-19
US20070104723A1 (en) 2007-05-10
IL174134A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
NO20055741D0 (no) Nye kjemiske forbindelser
NO20034056D0 (no) Proliferative sykdommer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
UA85559C2 (en) Aminobenzophenone compounds
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
SE0302304D0 (sv) Novel compounds
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
DE602005010258D1 (de) Behandlung von ballastwasser
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
DE602004012759D1 (de) Behandlung von fibrosen
ATE391489T1 (de) Haarbehandlungszusammensetzungen
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition